Seres Therapeutics Inc [MCRB] stock is trading at $0.88, up 2.10%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MCRB shares have gain 6.72% over the last week, with a monthly amount glided 48.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on October 24, 2024, when JP Morgan downgraded its rating to a Underweight. On April 21, 2023, JP Morgan initiated with a Neutral rating and assigned a price target of $7 on the stock. Goldman downgraded its rating to a Sell and decreased its price target to $7 on July 23, 2021. Chardan Capital Markets upgraded its rating to Buy for this stock on March 05, 2021, but kept the price target unchanged to $30. In a note dated September 18, 2020, Chardan Capital Markets downgraded an Neutral rating on this stock and revised its target price from $32.50 to $27.50.
Seres Therapeutics Inc [MCRB] stock has fluctuated between $0.54 and $2.05 over the past year. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $0.88 at the most recent close of the market. An investor can expect a potential return of 42.05% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
Seres Therapeutics Inc [NASDAQ:MCRB] reported sales of 0.06M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -108.88% with Operating Profit Margin at -2214.05%, Pretax Profit Margin comes in at -398.05%, and Net Profit Margin reading is -398.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is 0.61 and Total Capital is -1.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8426 points at the first support level, and at 0.8066 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9372, and for the 2nd resistance point, it is at 0.9958.
Ratios To Look Out For
For context, Seres Therapeutics Inc’s Current Ratio is 1.12. Further, the Quick Ratio stands at 1.12, while the Cash Ratio is 1.03. Considering the valuation of this stock, the price to sales ratio is 2552.76, the price to book ratio is 6.25.
Transactions by insiders
Recent insider trading involved DesRosier Thomas, Chief Legal Officer and EVP, that happened on Nov 18 ’24 when 878.0 shares were sold., von Moltke Lisa completed a deal on Nov 18 ’24 to sell 977.0 shares. Meanwhile, CEO and President Shaff Eric D. sold 2505.0 shares on Nov 18 ’24.
